Danish vaccine company will run studies in Africa while on the hunt for capital in Europe and USA

Biotech company Minervax is preparing phase II studies of its streptococcus infection vaccine in Uganda and South Africa and trying to raise money for studies in USA and Europe.

Photo: Sam Mednick/AP/Ritzau Scanpix

Log in to read our articles

Welcome to MedWatch. A part of our content is exclusive and reserved for our users.

Try MedWatch for 14 days.

Get a trial subscription here.

Do you want a trial subscription with multiple users for yourself and your colleagues?

Read more about your options and find the contact information to our sales team here.

Related articles